Increasingly, cardiometabolic syndromes including diabetes and obesity, are associated with occurrence of heart failure with diastolic dysfunction – including heart failure with preserved ejection fraction (HFpEF) and diabetic cardiomyopathy. Diagnosis of heart failure with diastolic dysfunction is independently associated with higher incidence of adverse clinical events. There is currently no specific treatment for diastolic dysfunction and therapies to manage symptoms have limited efficacy. Understanding of the cardiomyocyte origins of diastolic dysfunction is an important priority to identify new therapeutics. The goal of this investigation was to experimentally definein vitrostiffness properties (stress/strain) of cardiomyocytes derived from hearts of animals exhibiting diastolic dysfunctionin vivoin response to dietary induction of cardiometabolic disease.Mice fed a high-fat-sugar-diet (HFSD vs control) for at least 25 weeks exhibited glucose intolerance, obesity and diastolic dysfunctionin vivo(echo E/e’). Intact isolated paced cardiomyocytes were each functionally investigated in three states: non-loaded, loaded (‘afterload’) and stretched (‘pre-load’) configurations. Mean stiffness of HFSD cardiomyocytes was 70% higher than control. The E/e’ doppler ratio for the origin hearts was elevated by 35%. A significant relationship was identified between thein vitrostiffness of single cardiomyocytes (Youngs Modulus) and thein vivodysfunction severity (Doppler E/e’).In relation to lengthening/relaxation performance, in the loaded HFSD cardiomyocytes (vs CTRL) the decrement in maximal sarcomere lengthening rate was more accentuated. With stretch, the Ca2+transient decay time course was prolonged. In addition for HFSD the pacing-associated stiffness elevation was further increased and diastolic sarcomere length decreased, although diastolic Ca2+level was reduced. Our findings suggest a previously undescribed alteration in Ca2+-myofilament interaction contributes to stiffness in HFSD cardiomyocytes.This study provides the first quantitative analysis of intact cardiomyocyte stiffness and performance deficits associated with acquired cardiometabolic disease. The findings demonstrate that a component of the cardiac diastolic dysfunction in cardiometabolic disease derives from intrinsic cardiomyocyte mechanical abnormality. These data offer impetus for further investigation to achieve therapeutic targeting of the specific myofilament structural modifications conferring cardiomyocyte stiffness in cardiometabolic disease.